Abstract
Background: The transfer factor (TF) is the dialyzable extract of leukocytes with cellular immunity transfer properties. Its use has spread in the treatment of a wide range of immunologic, infectious, and even oncological diseases. However, important aspects in their protein profile, component concentrations, and a well-defined action mechanism are not completely unknown.
Objectives: To analyze the protein profiles of different transfer factors marketed in Mexico.
Methods: 6 TF marketed in Mexico were obtained and analyzed, quantifying protein with thaze Bradford method, by high-performance liquid chromatography (HPLC), and polyacrylamide gel electrophoresis (SDS-PAGE). All samples were analyzed in duplicate.
Results: The total protein concentrations of all TF analyzed are less than 0.2 mg/mL. The chromatographic profiles showed differences in some TF. The protein concentration was 6 to almost one thousand times lower compared to reports by some manufacturers.
Conclusion: Almost all transfer factors marketed in Mexico lack a labeling and health record that meets the official standards.
References
Lawrence HS. The transfer in humans of delayed hypersensitivity to streptococcal M substance and to tuberculin with disrupted leukocytes. J. Clin Invest. 1955;34(2):219-232. Disponible en: https://www. ncbi.nlm.nih.gov/pmc/articles/PMC438618/
Dupont B, Ballow M, Hansen JA, Quick C, Yunis EJ, Good RA. Effect of transfer factor therapy on mixed lymphocyte culture reactivity. Proc Natl Acad Sci USA. 1974;71(3):867-871. Disponible en: http://www. pnas.org/content/71/3/867.full.pdf
Lawrence HS, Pappenheimer AM Jr. Transfer of delayed hypersensitivity to diphtheria toxin in man. J Exp Med. 1956;104:321-335. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2136574/
Borkowsky W, Suleski P, Bhardwaj N, Lawrence HS. Antigen-specific activity of murine leukocyte dialysates containing transfer factor on human leukocytes in the leukocyte migration inhibition (LMI) assay. J Immunol. 1981;12681):80-82.
Lawrence HS. The transfer in humans of delayed skin sensitivity to streptococcal M substance and to tuberculin with disrupted leucocytes. J Clin Invest. 1955;34(2):219-230. Disponible en: https://www.ncbi. nlm.nih.gov/pmc/articles/PMC438618/
Kirkpatrick CH. Transfer factors: identification of conserved sequences in transfer factor molecules. Mol Med. 2000;6(4):332-341. Disponible en: http://static.smallworldlabs.com/molmedcommunity/content/ pdfstore/332.pdf
Kirkpatrick CH, Hamad AR, Morton LC. Murine transfer factors: dose-response relationships and routes of administration. Cell Immunol. 1995;164(2):203-206.
Sánchez-González DJ, Sosa-Luna CA, Vásquez-Moctezuma I. Factores de transferencia en la terapéutica médica. Med Clin. 2011;137(6):273-277. Disponible en: http://www.elsevier.es/es-revista-medicina-clinica-2-articulo-factores-transferencia-terapeutica-medica-S0025775310005774
García-Martín MC, Cruza-Cáceros M, Sánchez-Rodríguez A, Abdo-Rodríguez A. Factor de transferencia y extractos bacterianos en asmáticos con infecciones respiratorias a recurrentes. Alergia Inmunol Pediatr. 1998;17(4):124-127.
Gellin b, Modlin JF, Casadevall A, Pirofski LA. Adjunctive immune therapy for fungal infections. Clin Infect Dis. 2001;33(7):1048-1056. Disponible en: http://cid.oxfordjournals.org/content/33/7/1048.full
Aguilar-Ríos JM, León-Burgos V, Baeza-Bacab MA. [Acute asthma prevalence in children and teenagers from Merida, Yucatan, Mexico]. Rev Alerg Mex. 2009;56(1):3-8.
Flores-Sandoval G, Gómez-Vera J, Orea-Solano M, López-Tiro J, Serrano E, Rodriguez A, Estrada- Parra S, Jiménez-Saab N [Transfer factor as specific immunomodulator in the treatment of moderate-severe atopic dermatitis]. Rev Alerg Mex. 2005;52(6):215-220.
Viza D, Fudenberg HH, Palareti A, Ablashi D, De Vinci C, Pizza G. Transfer factor: an overlooked potential for the prevention and treatment of infectious diseases. Folia Biol (Praha). 2013;59(2):53-67.
Li C, Huang L, Wang Y, Li X, Liang S, Zheng Y. Preparation and properties of the specific anti-influenza virus transfer factor. Head Face Med. 2010;6(10):22. doi: 10.1186/1746-160X-6-22
Estrada-Parra S, Nagaya A, Serrano E, Rodriguez O, Santamaria V, Ondarza R, Chávez R, Correa B, Monges A, Cabezas R, Calva C, Estrada-García I. Comparative study of transfer factor and acyclovir in the treatment of herpes zoster. Int. J. Immunopharmacol. 1998;20(10):521-535.
Viza D. AIDS and transfer factor: myths, certainties and realities. Biotherapy. 1996;(1-3):17-26.
Russian Health Ministry. [Blog]. Ministry of Health and Social Development of Russian Federation. Transfer factor use in immunorehabilitation after infectious-imflamatory and somatic diseases. Methodological letter. Moscow, 2004. Disponible en: http://russianhealthministry.blogspot.mx/2008/01/6-conclusion.html?m=0
Goergescu C. Effect of long-term therapy with transfer factor in rheumatoid arthritis. Med Interne. 1985 23(2):135-140.
Lamoureux G, Cosgrove J, Duquette P, Lapierre Y, Jolicoeur R, Vanderland F. A clinical and immunological study of the effects of transfer factor on multiple sclerosis patients. Clin Exp Immunol. 1981;43(3):557- 564. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1537193/
Ojeda MO, van’t Veer C, Fernández-Ortega CB, Araña-Rosainz MJ, Buurman WA. Dailyzable leukocyte extract differentially regulates the production of TNF-alpha, IL-6 & IL-8, in bacterial component-activate leukocytes and endothelial cells. Inflamm Res. 2005;54(2):74-81.
Wang RN, Wang YB, Geng JW, Guo DH, Liu F, Chen HY, Zhang HY, Cui BA, Wei ZY. Enhancing immune responses to inactivated porcine parvovirus oil emulsion vaccine by co-inoculating porcine transfer factor in mice. Vaccine. 2012;30(35):5246-5252. doi: 10.1016/j.vaccine.2012.05.077
Viza D, Fudenberg HH, Palareti A, Ablashi D, De Vinci C, Pizza G. Transfer factor: an overlooked potential for the prevention and treatment of infectious diseases. Folia Biol (Praha). 2013;59(2):53-67. Disponible en: http://fb.cuni.cz/volume-59-2013-no-2#articFB2013A0007
Bradford MM. A rapid and sensitive method for the quantitation of micro-gram quantities of protein utilizing the principle of protein dye binding. Anal Biochem. 1976;72(1-2):248-254. doi:10.1016/0003-2697(76)90527-3
Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970;227(5259):680-685. doi:10.1038/227680a0
Farmacopea de los Estados Unidos Mexicanos. Undécima edición. México: Secretaría de Salud; 2014.
Norma Oficial Mexicana NOM-253-SSA1-2012, para la disposición de sangre humana y sus componentes con fines terapéuticos. Diario Oficial de la Federación 2012 Oct 26. Disponible en: http:// www.dof.gob.mx/nota_detalle.php?codigo=5275587&fecha=26/10/2012
Norma Oficial Mexicana NOM-072-SSA1-2012, etiquetado de medicamentos y de remedios herbolarios. Diario Oficial de la Federación 2012 Nov 21. Disponible en: http://dof.gob.mx/nota_detalle.php?codigo= 5278341&fecha=21/11/2012
Norma Oficial Mexicana NOM-059-SSA1-2015, buenas prácticas de fabricación de medicamentos. Diario Oficial de la Federación 2012 Oct 11. Disponible en: http://www.cofepris.gob.mx/MJ/Documents/ Normas/050216nom059.pdf
Norma Oficial Mexicana NOM-251-SSA1-2009, prácticas de higiene para el proceso de alimentos, bebidas o suplementos alimenticios. Diario Oficial de la Federación 2010 Mar 1. Disponible en: http:// dof.gob.mx/nota_detalle.php?codigo=5133449&fecha=01/03/2010
Norma Oficial Mexicana NOM-051-SCFI/SSA1-2010, especificaciones generales de etiquetado para alimentos y bebidas no alcohólicas preenvasados-Información comercial y sanitaria. Diario Oficial de la Federación 2010 Abr 5. Disponible en: http://dof.gob.mx/nota_detalle.php?codigo=5137518&fec ha=05/04/2010
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright (c) 2016 Revista Alergia México